Lymphoma Clinical Trials in Ohio

Showing 321-335 of 335 trials

Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma

NCT00003187

RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill cancer cells. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Eliminating the T cells from the donor cells before transplanting them may prevent this from happening. PURPOSE: Randomized phase II/III trial to compare the effectiveness of conventional bone marrow transplantation with T cell-depleted bone marrow transplantation in treating patients who have leukemia, myelodysplasia, or lymphoblastic lymphoma.

LeukemiaLymphomaMyelodysplastic Syndromes

Virginia Commonwealth University19 participantsStarted May 1995

Stanford, California, United States • Iowa City, Iowa, United States • Lexington, Kentucky, United States +10 more locations

TERMINATEDPHASE268 miles

A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell Lymphoma

NCT00843050

The purpose of this study is to determine whether P276-00 is safe and effective in treatment of Mantle Cell Lymphoma that is recurred after or not responding to at least one previous line of treatment.

Mantle Cell Lymphoma

Piramal Enterprises Limited13 participantsStarted Nov 2009

Phoenix, Arizona, United States • Scottsdale, Arizona, United States • Rochester, Minnesota, United States +17 more locations

PreviousPage 17 of 17

Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma

A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell Lymphoma

Lymphoma Trials in Other Cities

Forodesine in the Treatment of Cutaneous T-Cell Lymphoma

Alemtuzumab in Treating Patients With Waldenstrom's Macroglobulinemia

A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's Lymphoma

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies

Phase 1 Study of MDX-1401 in Patients With CD30-positive Refractory/Relapsed Hodgkin's Lymphoma

Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients

BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma

Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia

A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies

DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas

Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma

Other Conditions in Ohio